Clinical Hematology International

In Press, Uncorrected Proof, Available Online: 21 May 2020

Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)

Authors
Uttam K. RaoORCID, Brian G. Engelhardt*
Department of Medicine, Vanderbilt University Medical Center, Nashville, Medical Center Drive, TN, USA
*Corresponding author. Tel.: 615-936-0381, Fax: 615-936-1812. Email: brian.engelhardt@vumc.org
Corresponding Author
Brian G. Engelhardt
Received 20 March 2020, Accepted 4 May 2020, Available Online 21 May 2020.
DOI
https://doi.org/10.2991/chi.d.200506.002How to use a DOI?
Keywords
ST2, IL-33, PTDM
Abstract

Patients undergoing allogeneic hematopoietic cell transplantation (HCT) are at risk for numerous acute and long-term complications from this procedure. Post-transplant diabetes mellitus (PTDM) is a common but under-recognized problem. Similar to graft-versus-host disease (GVHD), new-onset diabetes is characterized by immune dysregulation that can negatively impact transplant outcomes. This review will discuss the biology of IL-33/ST2 in acute GVHD and PTDM development, and how this cytokine axis could be leveraged for predicting and treating immuno-metabolic complications after transplant.

Copyright
© 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

Journal
Clinical Hematology International
Publication Date
2020/05
ISSN (Online)
2590-0048
DOI
https://doi.org/10.2991/chi.d.200506.002How to use a DOI?
Copyright
© 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Uttam K. Rao
AU  - Brian G. Engelhardt
PY  - 2020
DA  - 2020/05
TI  - Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)
JO  - Clinical Hematology International
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.200506.002
DO  - https://doi.org/10.2991/chi.d.200506.002
ID  - Rao2020
ER  -